Osimertinib (AZD9291) increases radio-sensitivity in EGFR T790M non-small cell lung cancer

Osimertinib (AZD9291) is a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has demonstrated significant clinical benefits in patients with EGFR-sensitizing mutations or the T790M mutation. However, the potential therapeutic effect of osimertinib combined with...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Nannan, Wang, Linlin, Meng, Xiangjiao, Wang, Jia, Zhu, Lifang, Liu, Changting, Li, Shaorong, Zheng, Li, Yang, Zhenfan, Xing, Ligang, Yu, Jinming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278463/
https://www.ncbi.nlm.nih.gov/pubmed/30365094
http://dx.doi.org/10.3892/or.2018.6803

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278463/
https://www.ncbi.nlm.nih.gov/pubmed/30365094
http://dx.doi.org/10.3892/or.2018.6803

Ejemplares similares